BTC Health Ltd Registered · ASX:BTC
BTC Health Ltd Registered — BTC Health — FY2024 Earnings Presentation
20 slides from BTC Health Ltd Registered's earnings presentation, Aug 28, 2024
Slide 1: Results & Operations Update
For personal use only & OPERATIONS UPDATE 28 AUGUST 2024 ASX: BTC www.btchealth.com.au
Slide 2: Disclaimer
Disclaimer Summary information This Presentation contains summary information about BTC health, and its activities current as at 28/8/2024. The information in the presentation is of a general For personal use only nature and does not purport to be complete or comprise all information which a shareho
Slide 3: Our mission (Executive Chairman quote)
For personal use only “Our mission is to distribute innovative and class-leading medical products, collaborating closely with healthcare professionals. By doing so, we empower patients to resume their daily passions and pursuits.” Executive Chairman Dr. Richard Treagus 3
Slide 4: Group Structure
Group Structure For personal use only BTC Health Ltd BTC Speciality BTC Cardio PL BTC Pharma PL Health PL Post-Operative Neuro-Spinal Cardio-thoracic Critical Care Specialised Pain Therapeutics BTC health is a registered Pooled Development Fund (PDF) in Australia. It is a type of venture capital fun
Slide 5: BTC Health Statutory Results – FY24 vs FY23
BTC Health Statutory Results – FY24 vs FY23 For personal use only FY24 ($) FY23 ($) Interest Income 16,360 13,260 Gain/(Loss) on investments 1,714,809 (9,619,890) Corporate Expenses 675,886 561,228 Profit/(Loss) Before Tax 1,055,287 (10,167,862) Profit/(Loss) for the Period 1,055,287 (10,167,862) 5
Slide 6: FY24 Financial Highlights
BTC health and investee companies FY24 Financial Highlights Group Revenue* Gross Profit • YOY improvement delivered across all key For personal use only $8.2m $3.6m financial and operational performance metrics. +5.1% YoY +17.1% YoY • New strategic investors have contributed towards growth, improvin
Slide 7: FY24 Key Financial Metrics
FY24 Key Financial Metrics Gross Profit Percentage Group Sales* Gross Profit For personal use only 45% $3.6M 43% $8.2M $3.3M $3.1M $7.7M $7.8M $2.9M 40% 39% $7.2M FY21 FY22 FY23 FY24 FY21 FY22 FY23 FY24 FY21 FY22 FY23 FY24 EBITDA of Investee Group Operating Costs Group EBITDA Companies $3.8M $3.9M $
Slide 8: Milestones Achieved in FY24
Milestones Achieved in FY24 8 new partnership For personal use only agreements for innovative, high- Share register quality products enhanced with 3 new strategic Strong cash investors position ($2.3m) Revenue No debt (+5.1%) Prudent Gross Profit management, (+17.1%) consolidation and strategic grow
Slide 9: BTC health – Our Strategy
BTC health – Our Strategy For personal use only Our Advantage The Growth Opportunity • World-class capabilities, ISO 13485 • Rising consumer and government certification, deep industry expertise, healthcare spending. and strong medical leadership. • Ageing populations and rapid • An agile, results-d
Slide 10: Distribution and Sales Network
Infrastructure and Our Tier 1 Customers Customer Reach For personal use only BTC health – Distribution and Sales Network Daily deliveries to 350+ hospitals (metro) and 48hr delivery (regional) 10
Slide 11: Direct Access to the Hospital Market
Direct Access to the Hospital Market For personal use only Australian Market New Zealand Market Public Hospitals Public Hospitals 1,450+ Hospitals • 695 Public Hospitals • 84 Public Hospitals Australasia wide • $67 billion expenditure in public • $12.5 billion expenditure in hospitals public hospita
Slide 12: Post-operative pain
Post-operative pain Infusion pumps and consumables For personal use only In 2022, there were 51,894 hip replacements in Australia and 67,742 knee replacements. Both procedures involve a post-operative recovery process where an electronic, portable infusion pump is applied for acute and chronic drug
Slide 13: Neuro-spinal
Neuro-spinal IZI Medical For personal use only Innovative medical devices and single-use products used in radiology and oncology, radiation therapy, neuro-spine, and image-guided surgery procedures. Ilumark Products focusing on sterile single-use retro-reflective marker spheres for image-guided and
Slide 14: Cardiothoracic and Critical Care
Cardiothoracic and Critical Care CPB - Cardiopulmonary Bypass For personal use only In 2022 across public and private hospitals in Australia1, there were • 12,700 coronary artery bypass graft procedures • 12,000 heart valve repair or replacement procedures, and • 129 heart transplants Each of those
Slide 15: Cardiothoracic and Critical Care – PEARS
Cardiothoracic and Critical Care PEARS For personal use only BTC Cardio entered into a distribution agreement with Exstent in FY24 to distribute its ExoVasc medical device, aka Personalised External Aortic Root Support (PEARS). 50 patients received an ExoVasc device implant in 2023, and BTC forecast
Slide 16: Pharmaceutical – Bronchitol and Aridol
Pharmaceutical Bronchitol and Aridol For personal use only Bronchitol is a PBS-listed treatment for Cystic Fibrosis (CF), a disease that affects more than 3,700 people in Australia and requires ongoing treatment. Bronchitol is manufactured in Australia with BTC Pharma having acquired the exclusive A
Slide 17: Operations Update
Operations Update • FY24 was a year of change, consolidation and a decisive “re-set”. For personal use only • Effectively managed the challenge of losing our largest product supplier in April 2023. • Cost-out exercise completed in Q1 FY24- created a more agile and efficient overhead structure and ex
Slide 18: Strong Foundation Established
Strong Foundation Established BTC health is stronger, having overcome a period of disruption and change. For personal use only BTC health has executed successfully on: • Containing overhead costs; Customers • Selling through ambIT infusion pump inventory; 517 • Making applications for listing new in
Slide 19: Building Momentum into FY25
Building Momentum into FY25 Areas of Focus For personal use only • Converting ambIT infusion pump users across to Rhythmic • Converting competitors across to Elasto-Q infusion pumps • Expanding reach and range of neurospinal products • Increasing adoption of our ECMO and CPB products • Further new p
Slide 20: Thank You
Thank You For personal use only Dr. Richard Treagus Joshua Kahanovitz Executive Chairman Head Of Finance Level 1, 10 Oxley Road, Hawthorn VIC 3122 101/568 Oxford St, Bondi Junction, NSW 2022 Australia Australia rtreagus@btchealth.com.au jkahanovitz@btchealth.com.au +61 417 520 509 +61 451 321 214 ww